ReviewNature reviews. Neurology2013
Treatment trials in progressive MS--current challenges and future directions.
Review in Nature reviews. Neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Neuroimaging markers and disability scales in multiple sclerosis: A systematic review and meta-analysis.PloS one · 2024Pooled it
- The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.Journal of neurology · 2022Trial
- Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.European journal of clinical pharmacology · 2019Trial
- Systematic Analysis of Alternative Splicing in Transcriptomes of Multiple Sclerosis Patient Brain Samples.International journal of molecular sciences · 2025Article
- Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.Journal of neurology, neurosurgery, and psychiatry · 2025Article
- A comparison of clinical outcomes in PPMS in the INFORMS original trial data set.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Article
- Teriflunomide attenuates neuroinflammation-related neural damage in mice carrying human PLP1 mutations.Journal of neuroinflammation · 2018Article
- Progressive multiple sclerosis, cognitive function, and quality of life.Brain and behavior · 2018Article
- Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.Neurology · 2017Observational
- Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.Neurology(R) neuroimmunology & neuroinflammation · 2017Article
- Review
- Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.Annals of neurology · 2015Article
- The promise of futility trials in neurological diseases.Nature reviews. Neurology · 2015Review
- Cortical excitability changes over time in progressive multiple sclerosis.Functional neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of immunomodulatory treatments has transformed the management of patients with relapsing-remitting multiple sclerosis (MS), but has had no consistent benefit in progressive MS. Patients with primary or secondary progressive MS, therefore, are faced with relentless functional decline that remains without treatment. Clinical trials in progressive MS are clearly needed, but their design and conduct is challenging, and different from that of trials in relapsing-remitting MS. Challenges to reliable measurement of clinical progression, uncertainties about the natural history of progressive MS, and the unclear role of imaging outcomes all impede optimal trial design. Clinical trials in progressive MS have used time to a predefined change on the Expanded Disability Status Scale as their main outcome measure, which has had important consequences for trial duration and has led to inclusion of only a highly selected minority of patients. Here, we review the current approach to clinical trial design in progressive MS, outline key ongoing challenges, and suggest strategies to overcome such hurdles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.